A phase Ib/II single-arm study evaluating the safety and efficacy of combined immunotherapy with mFOLFOX6, bevacizumab and atezolizumab in advanced-stage biliary cancer
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Biliary cancer
- Focus Therapeutic Use
- Acronyms COMBATBIL
- 05 Oct 2021 Planned initiation date changed from 1 Sep 2021 to 1 Oct 2021.
- 22 Jul 2021 New trial record